Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Multiple sclerosis: an immune or neurodegenerative disorder?
Imaging Neurodegeneration and Repair in Multiple Sclerosis
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease.
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
CNS myelin wrapping is driven by actin disassembly.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
Tecfidera(®): an approach for repurposing.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Neuroprotective effect of masitinib in rats with postischemic stroke.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.

Pages